Syros Pharma Teams Up with Global Blood Therapeutics to Fight Sickle Cell Disease
Source: Streetwise Reports  (12/18/19)
Syros Pharmaceuticals' shares rose 20% today after the firm reported that it entered into a collaboration agreement with Global Blood Therapeutics for development of therapies for sickle cell disease and beta thalassemia that could result in payments to Syros as high as $315 million over three years. More >

Biopharma to Test Immunity Activator in Advanced Solid Cancers
Source: Streetwise Reports  (12/17/19)
The company's plans for and approach to one of its most advanced drug candidates are discussed in an H.C. Wainwright & Co. report. More >

Biopharma 'Keeps Executing and Securing Milestones'
Source: Streetwise Reports  (12/17/19)
The company's latest achievement and partnership potential are addressed in a ROTH Capital Partners report. More >

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome
Source: Streetwise Reports  (12/16/19)
Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application filing in H2/20. More >

Sarepta Shares Get a 35% Boost from FDA Approval of 2nd DMD Drug
Source: Streetwise Reports  (12/13/19)
Sarepta Therapeutics shares traded 35% higher after the firm reported that the FDA approved its second RNA exon-skipping treatment drug VYONDYS 53 injection for the treatment of Duchenne's Muscular Dystrophy in patients amenable to skipping Exon 53. More >

Assertio Therapeutics' Shares Jump 50% on Sale of Shingles Pain Drug to Alvogen
Source: Streetwise Reports  (12/12/19)
Assertio Therapeutics' shares rose 50% today after the firm reported that it has agreed to sell all rights to its Gralise drug used in the treatment of pain from shingles to Alvogen for $127.5 million. The transaction is expected to close in January 2020. More >

Proteostasis Therapeutics Reports Positive Results from European Cystic Fibrosis Research
Source: Streetwise Reports  (12/11/19)
Proteostasis Therapeutics' shares traded higher today after the company reported positive results in its European Cystic Fibrosis study of organoids grown from human stem cells. The firm believes the ongoing ex-vivo study supports initiation of a human clinical trial in mid-2020, and potential for a Marketing Authorization Application in 2021. More >

Avid Bioservices' Shares Rise on Q2/20 Earnings and Confirmed Outlook
Source: Streetwise Reports  (12/10/19)
Shares of Avid Bioservices traded higher today, reaching a new 52-week high, after the firm reported Q2/20 earnings and reaffirmed its revenue guidance for Full-Year 2020. More >

Analyst Believes Biopharma's Alzheimer's Treatment Could Be Superior to Biogen's
Source: Streetwise Reports  (12/10/19)
How this company's Alzheimer's therapeutic compares to an advanced-stage competitor is outlined in a Dawson James Securities note. More >

ArQule Shares Double on Proposed $2.7 Billion Tender Offer from Merck
Source: Streetwise Reports  (12/9/19)
ArQule Inc. shares traded more than 100% higher today after the company entered into definitive agreement to be acquired by a Merck subsidiary company for $20 per share. The deal is valued at $2.7 billion and is expected to close in the early part of Q1/20. More >

Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data
Source: Streetwise Reports  (12/6/19)
Shares of Cassava Sciences traded 20% higher after the firm presented additional data from the Phase 2a study of its investigational drug candidate PTI-125 for Alzheimer's disease to the Clinical Trials on Alzheimer's Disease conference in San Diego, Calif. More >

Aurinia Pharma Shares Open 100% Higher on Phase 3 Lupus Data
Source: Streetwise Reports  (12/5/19)
Shares of Aurinia Pharmaceuticals traded much higher today after it reported positive results from its Phase 3 AURORA trial of Voclosporin for treatment of lupus nephritis. The company plans to submit a New Drug Application to the FDA in H1/20. More >

Immuno-Oncology Firm Expands Agreement with AbbVie
Source: Streetwise Reports  (12/4/19)
The revisions to the existing arrangement between the two U.S. firms are discussed in a ROTH Capital Partners report. More >

INmune Bio Targeting Cancer, Alzheimer's and NASH Simultaneously
Source: Daniel Carlson for Streetwise Reports  (12/4/19)
Daniel Carlson of Tailwinds Research initiates coverage on this clinical-stage biotech whose drug candidate works to strengthen the innate immune system. More >

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results
Source: Streetwise Reports  (12/4/19)
Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher today after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. More >

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial
Source: Streetwise Reports  (12/3/19)
Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. More >

Kodiak Shares Soar on $225 Million Royalty Deal for Retinal Drug
Source: Streetwise Reports  (12/2/19)
Shares of Kodiak Sciences traded more than 100% higher at times after the company reported that it entered into a $225 million royalty agreement for the firm's KSI-301 used in the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases. More >

Coverage Initiated on Maker of Antibiotic-Free Supplement for Livestock Feed
Source: Streetwise Reports  (11/26/19)
The highlights of this investment story are outlined in a Zacks Small-Cap Research report. More >

ChemoCentryx Shares Spike 300% on Phase 3 ANCA Vasculitis Trial Results
Source: Streetwise Reports  (11/26/19)
Shares of ChemoCentryx Inc. opened greater than 330% higher today after the firm reported positive topline data from its pivotal Phase 3 ADVOCATE trial of Avacopan in treatment of ANCA-associated vasculitis. More >

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment
Source: Streetwise Reports  (11/25/19)
Shares of Intercept Pharmaceuticals rose today after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. More >

EyeGate Pharma Shares Looking Up on Pivotal PRK Ocular Bandage Gel Study Data
Source: Streetwise Reports  (11/22/19)
EyeGate Pharmaceuticals shares opened nearly 85% higher today after the company reported select topline data demonstrating that it met its primary endpoint in its cornea wound repairs pivotal photorefractive keratectomy study using the firm's Ocular Bandage Gel eye drop. More >

Hepion Pharma Shares Climb 50% Higher on NASH Liver Disease Treatment Results
Source: Streetwise Reports  (11/21/19)
Shares of Hepion Pharmaceuticals opened higher today after the company reported that its anti-fibrotic agent CRV431 prevented the development of liver cirrhosis in a highly aggressive, preclinical liver disease model. More >

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug
Source: Streetwise Reports  (11/20/19)
Shares of Kiniksa Pharmaceuticals opened nearly 30% higher today after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. More >

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data
Source: Streetwise Reports  (11/19/19)
Shares of Myovant Sciences opened 120% higher today after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a New Drug Application in Q2/20. More >

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data
Source: Streetwise Reports  (11/18/19)
Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. More >